Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 119.60 0.00%
CORT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.93B
- P/E (TTM)
- 265.78
- Forward P/E
- 27.17
- EPS (TTM)
- $0.45
- Dividend yield
- None
- 52-week range
- 28.66 – 126.38
- Day range
- 117.23 – 122.00
- Volume / Avg
- 628.05K / 1.31M
- Beta
- —
- Shares outstanding
- 108.10M
- Next earnings
- Nov 3, 2026
52-week range
CORT stock today
On Oct 7, CORT ended the session at $119.60, adding $0.03 (0.03%), versus the S&P 500's 0.22% decline. Trading was light, with 628.05K shares changing hands, about 48% of the average daily volume. At this level, CORT sits near the top of its 52-week range of $28.66 to $126.38: 5.4% below the high, set on Aug 25, 2026 and 317.3% above the low.
CORT is up 243.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 32.4%. At 265.8x trailing earnings, Corcept Therapeutics trades above the peer-group median of 22.7x. Its forward P/E of 27.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Corcept Therapeutics's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Corcept Therapeutics
Company profileCorcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Joseph K. Belanoff M.D.
- Headquarters
- Redwood City, CA
- Employees
- 730
- IPO year
- 2004
- Website
- corcept.com
Financial highlights
Full financialsIn fiscal 2025, Corcept Therapeutics generated $761.4 million in revenue, up 12.8% from fiscal 2024, its 13th consecutive year of revenue growth. Net income was $99.7 million (-29.4% year over year), for a net margin of 13.1% versus a median of 25.2% in the prior 5 years. Gross margin was 98.3% (down from 98.4%) and operating margin 5.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M |
| Growth | +12.79% | +39.94% | +20.04% | +9.80% | +3.42% |
| Net income | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M |
| EPS (diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$141.00+17.89%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.68
- Last reported (Q2 2026)
- Jul 29, 2026
- EPS actual vs est.
- $0.36 vs —
CORT news
All CORT newsCorcept Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs CORT |
| SMMTSummit Therapeutics Inc. | 17.95 | +3.70% | $14.32B | vs CORT |
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs CORT |
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs CORT |
| JAZZJazz Pharmaceuticals plc | 231.19 | -0.09% | $15.01B | vs CORT |
| ASNDAscendis Pharma A/S | 228.41 | +1.04% | $15.03B | vs CORT |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs CORT |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs CORT |
Indexes, lists and sector
Corcept Therapeutics stock FAQ
What is Corcept Therapeutics's stock price today?
CORT last traded at $119.60 as of Oct 7, 4:00 PM EDT, up 0.03% on the day. Prices are delayed at least 15 minutes.
When is Corcept Therapeutics's next earnings date?
Corcept Therapeutics is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.68.
What is CORT's P/E ratio?
CORT trades at a trailing P/E ratio of 265.78 and a forward P/E of 27.17, compared with a median of 22.7 for its closest peers.
Who is Corcept Therapeutics's CEO?
Dr. Joseph K. Belanoff M.D. is the chief executive officer of Corcept Therapeutics Incorporated, which has about 730 employees.
What is the CORT 52-week high?
The 52-week high for CORT is $126.38 and the 52-week low is $28.66. The stock is currently 5.4% below its high.